ASCO Annual Meeting

An immunotherapy agent that targets the PD-1 pathway demonstrated response rates as high as 28% in an early-phase study involving patients with different tumor types.

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on Dabrafenib and Trametinib Combination Side Effects

Pharmaceutical industry analysts and companies have been weighing in on their selections for the most noteworthy research to be presented during the 2012 ASCO Annual Meeting.

American Society of Clinical Oncology (ASCO) 2012 Annual Meeting video highlights, from OncLive TV.

On May 16, the ASCO highlighted the results of five ground-breaking studies in advance of its annual meeting held in Chicago from June 1-5, 2012.

Dr. Andre Goy, from John Theurer Cancer Center, Highlights Research From the 2012 ASCO Meeting.

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on the Unique Attributes of Neoadjuvant Zytiga.

Dr. Maurie Markman, from Cancer Treatment Centers of America, on Awareness of Long-Term Chemotherapy Side Effects

Dr. Andrew Goy, from John Theurer Cancer Center, on Neoadjuvant Hormonal Therapy Plus Zytiga

Combined neoadjuvant treatment with abiraterone acetate (Zytiga) plus standard hormonal therapy before prostatectomy eradicated or nearly eradicated tumors in 34% of patients with localized high-risk prostate cancer.

A combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib has shown promising activity in patients with advanced melanoma.

Olanzapine, an antipsychotic medication that is often used off-label, has proved highly effective in controlling breakthrough chemotherapy-induced nausea and vomiting.

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on Neoadjuvant Hormonal Therapy Combined With Abiraterone Acetate

Dr. Paul Chapman, from Memorial Sloan-Kettering Cancer Center, on Combining BRAF and MEK Inhibitors for Advanced Melanoma

Dr. Maurie Markman, Cancer Treatment Centers of America, on Primary Care Physician Awareness of Long-Term Chemotherapy Side Effects

Many primary care providers and some oncologists are unaware of the long-term effects of four chemotherapy drugs used to treat two of the most common forms of cancer.

Dr. Andre Goy, from John Theurer Cancer Center, on Crizotinib for Pediatric Patients With ALCL

Targeting the ALK gene with the oral agent crizotinib slowed or eliminated signs of tumor growth in pediatric patients with aggressive forms of neuroblastoma, ALCL, and IMTs.

Dr. Shayma Kazmi, from Cancer Treatment Centers of America, on Olanzapine for Breakthrough Chemotherapy-Induced Nausea and Vomiting

OncLive.com will be on-site at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.

American Society of Clinical Oncology (ASCO) 2011 Annual Meeting Daily Picture Slideshow

Cabozantinib (XL184), a novel tyrosine kinase inhibitor, caused the deaths of 6 patients in a phase II clinical trial.

Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada discusses mortalities in cabozantinib trial.

Women who present with BRCA1 and BRCA2 mutation face an increased risk of breast and ovarian cancer.

Dr. Infante from Sarah Cannon Research Institute Talks About BRAF Mutation Testing

Phosphatase and tensin homolog (PTEN)-positive breast cancer can be treated with trastuzumab (Herceptin) as effectively as PTEN-negative breast cancer

American Society of Clinical Oncology 2011 Annual Meeting Picture Slideshow Day Four

Axitinib demonstrated significantly better progression-free survival (PFS) compared with sorafenib